Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men

Kidney International

Volumn 70, Issue 12, 2006, Pages 2141-2147

  Nishida, Y ^a   Taketani, Y ^a   Yamanaka Okumura, H ^a   Imamura, F ^b   Taniguchi, A ^a   Sato, T ^a   Shuto, E ^a   Nashiki, K ^a   Arai, H ^a   Yamamoto, H ^a   Takeda, E ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TUFTS UNIVERSITY   (United States)

Author keywords

Fibroblast growth factor 23; Parathyroid hormone; Phosphorus metabolism; Postprandial change

Indexed keywords

CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; BLOOD LEVEL; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CLINICAL STUDY; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE METABOLISM; PHOSPHATE URINE LEVEL; POSTPRANDIAL STATE; PRIORITY JOURNAL; TEST MEAL; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; CALCIUM; CROSS-OVER STUDIES; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; MALE; PARATHYROID HORMONE; PHOSPHATES; VITAMIN D;

EID: 33845322655     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002000     Document Type: Article

References (28)

1. Berndt TJ, Knox FG. Renal regulation of phosphate excretion. In: Seldin DW, Diebish G (eds). The Kidney, Physiology and Pathophysiology, 2nd edn. Raven press: New York, 1992, pp 2511-2532.
2. Murer H, Biber J. Renal tubular phosphate transport. In: Seldin DW, Diebish G (eds). The Kidney, Physiology and Pathophysiology, 2nd edn. Raven press: New York, 1992, pp 2481-2509.
3. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 2000; 80: 1373-1409.
4. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505.
5. Rowe PSN, de Zoysa PA, Dong R et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000; 67: 54-68.
6. Berndt T, Craig TA, Bowe AE et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 2003; 112: 785-794.
7. Takeda E, Yamamoto H, Nashiki K et al. Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med 2004; 8: 191-200.
8. Berndt TJ, Schiavi S, Kumar R. 'Phosphatonins' and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 2005; 289: F1170-F1182.
9. Yu X, White KE. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 2005; 16: 221-232.
10. Shimada T, Muto T, Urakawa I et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143: 3179-3182.
11. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
12. Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18: 1227-1234.
13. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 4957-4960.
14. Takeuchi Y, Suzuki H, Ogura S et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004; 89: 3979-3982.
15. Larsson T, Nisbeth U, Ljunggren Ö. et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279.
16. Imanishi Y, Inaba M, Nakatsuka K et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65: 1943-1946.
17. 3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549.
18. 2D metabolism in mice. Endocrinology 2005; 146: 5358-5364.
19. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524.
20. Martin DR, Ritter CS, Slatopolsky E, Brown AJ. Acute regulation of parathyroid hormone by dietary phosphate. Am J Physiol Endocrinol Metab 2005; 289: E729-E734.
21. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095.
22. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149.
23. Burnett SA, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21: 1187-1196.
24. Reiss E, Canterbury JM, Bercovitz MA, Kaplan EL. The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest 1970; 49: 2146-2149.
25. Calvo MS, Heath III H. Acute effects of oral phosphate-salt ingestion on serum phosphorus, serum ionized calcium, and parathyroid hormone in young adults. Am J Clin Nutr 1988; 47: 1025-1029.
26. Portale AA, Halloran BP, Morris Jr RC. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 1987; 80: 1147-1154.
27. Syal A, Schiavi S, Chakravarty S et al. Fibroblast growth factor-23 increases mouse PGE2 production in vivo and in vitro. Am J Physiol Renal Physiol 2006; 290: F450-F455.
28. Ito N, Fukumoto S, Takeuchi Y et al. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 2005; 23: 435-440.